RISUG: an intravasal injectable male contraceptive

Indian J Med Res. 2014 Nov;140 Suppl(Suppl 1):S63-72.


Over the last two decades RISUG has been drawing attention in the field of male contraception. It promises to sterile men for a period of up to 10-15 years. According to recent studies in animal models, it proves to be completely reversible. Practically, there are no better options available that can assure complete sterility and precise reversibility. Regardless of so much of information available, RISUG is still holding up for many reasons, firstly, the available information engender bewilderment such as what is this copolymer, how does it work and is reversal really possible? Secondly, advancement of this outstanding invention is drastically slow and thirdly, effects of long-term contraception with RISUG and reports on evaluation of anomalies (if any) in F 1 , F 2 progenies, are lacking. In this review the lacunae as well as advances in the development of RISUG in the light of published work and available resources are pointed out. Formulation of the RISUG, its mode of action and clinical trials have been addressed with particular emphasis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic
  • Contraception / economics
  • Contraception / methods*
  • Contraceptive Agents, Male / administration & dosage*
  • Contraceptive Agents, Male / pharmacology*
  • Dimethyl Sulfoxide / metabolism
  • Humans
  • Injections
  • Male
  • Maleic Anhydrides / metabolism
  • Styrene / metabolism
  • Vas Deferens / metabolism*


  • Contraceptive Agents, Male
  • Maleic Anhydrides
  • Styrene
  • Dimethyl Sulfoxide